Biotech startups that raised Series A in DACH
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Cellbox Solutions | Cologne | Series A | $1.7M | 2026-10-20 |
| Adaptyv Biosystems | Lausanne | Series A | $40.0M | 2026-08-25 |
| mbiomics | Munich | Series A | $12.0M | 2026-04-28 |
| Kupando | Schönefeld | Series A | $11.5M | 2026-03-18 |
| Leman Biotech | Lausanne | Series A | $28.8M | 2026-01-26 |
| FoRx Therapeutics | Basel | Series A | $50.0M | 2025-12-18 |
| Comphya | Lausanne | Series A | $4.0M | 2025-07-08 |
| Adiposs | Geneva | Series A | $5.0M | 2025-06-30 |
8 rows of the CSV in 5 of its 18 columns.
- The 130 biotech startups in DACH whose last round is Series A have raised $1.6B in total.
- 12 of them closed their most recent round in the last 12 months, $214.3M combined.
- The largest of those rounds is FoRx Therapeutics' $50.0M Series A, dated December 2025.
- The most recent is Cellbox Solutions' $1.7M Series A on 20 October 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 22 of them, more than any other fund.
- Health care is the most common other sector, with 102 companies (78%).
- 16% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 11 to 50 employees (51% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 130| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Cellbox Solutions | Cellbox Solutions provides logistics solutions for the global biomedical industry. | Biotech | Cologne, Germany | Series A | $1.7M | 2026-10-20 | $15.3M | European Innovation Council, Fraunhofer Venture, CK Venture Capital | 11 to 50 | 2017 |
| Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| mbiomics | mbiomics is a biotechnology company. | Biotech | Munich, Germany | Series A | $12.0M | 2026-04-28 | $26.1M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital | 11 to 50 | 2020 |
| Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld, Germany | Series A | $11.5M | 2026-03-18 | $24.0M | HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 | 1 to 10 | 2018 |
| Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne, Switzerland | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| Comphya | Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. | Biotech | Lausanne, Switzerland | Series A | $4.0M | 2025-07-08 | $14.2M | Venture Kick, Verve Ventures, Nest Collective Foundation | 1 to 10 | 2017 |
| Adiposs | Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. | Biotech | Geneva, Switzerland | Series A | $5.0M | 2025-06-30 | $7.4M | MassChallenge, Venture Kick, FONGIT Innovation Fund +2 | 1 to 10 | 2020 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Basel, Switzerland | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| invIOs | invIOs is a private biotech company that discovers and develops cancer therapies. | Biotech | Vienna, Austria | Series A | $8.9M | 2024-10-15 | $12.9M | The Austrian Research Promotion Agency (FFG), Ligand Pharmaceuticals | 11 to 50 | 2019 |
| Mindpeak | Mindpeak develops AI-based diagnostic software that detects, quantifies, and classifies cancer. | Artificial intelligence | Hamburg, Germany | Series A | $15.3M | 2024-09-30 | European Innovation Council, EIC Accelerator, Nina Capital +2 | 11 to 50 | 2018 | |
| PL BioScience | PL BioScience delivers 2D and 3D cell culture solutions based on human Platelet Lysate. | Biotech | Aachen, Germany | Series A | $8.5M | 2024-08-08 | $13.0M | TechVision Fund, better ventures, Brightlands Venture Partners +1 | 11 to 50 | 2015 |
| Neurosterix | Neurosterix is a biopharmaceutical firm creating allosteric modulators for neurological illnesses. | Biotech | Geneva, Switzerland | Series A | $65.0M | 2024-04-03 | $65.0M | Perceptive Advisors, Xontogeny, Acorn Bioventures | 11 to 50 | 2024 |
| G.ST Antivirals | G.ST Antivirals is a clinical-stage biotech company developing broad-spectrum antivirals for respiratory tract infections. | Biotech | Vienna, Austria | Series A | $6.7M | 2024-01-25 | Lansdowne Partners, XISTA Science Ventures | 11 to 50 | 2019 | |
| Scailyte | Scailyte delivers precision medicine through single-cell science. | Artificial intelligence | Basel, Switzerland | Series A | $1.8M | 2023-12-04 | $15.6M | Venture Kick, Verve Ventures, Innosuisse +2 | 11 to 50 | 2017 |
| traceless materials | traceless materials develops circular bioeconomy alternatives to conventional plastics and bioplastics. | Biotech | Hamburg, Germany | Series A | $38.8M | 2023-09-25 | HTGF (High-Tech Gruenderfonds), European Innovation Council, Planet A Ventures +2 | 51 to 100 | 2020 | |
| TOLREMO therapeutics | TOLREMO therapeutics develops small molecules that target drug resistance pathways in cancer therapy. | Biotech | Zürich, Switzerland | Series A | $37.9M | 2023-09-20 | Altos Ventures, redalpine, BioMedPartners +1 | 11 to 50 | 2017 | |
| NewBiologix | NewBiologix is a technology innovation company. | Biotech | Epalinges, Switzerland | Series A | $50.3M | 2023-05-11 | $50.3M | Recipharm Venture Fund | 11 to 50 | 2023 |
| anvajo | anvajo is a Dresden-based company that develops, manufactures and sells liquid analysis solutions. | Biotech | Dresden, Germany | Series A | $17.3M | 2022-10-19 | Think.Health, Die Brückenköpfe, Johnsonville Ventures | 51 to 100 | 2016 | |
| Vector BioPharma | Vector BioPharma develops gene precision delivery technology to improve biologics. | Biotech | Basel, Switzerland | Series A | $30.0M | 2022-08-10 | $30.0M | Versant Ventures | 11 to 50 | 2021 |
| CDR-Life AG | CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. | Biotech | Schlieren, Switzerland | Series A | $76.0M | 2022-04-13 | $76.0M | RA Capital Management, Omega Funds, Jeito Capital | 51 to 100 | 2017 |
| Cimeio Therapeutics | Cimeio Therapeutics develops curative treatments for genetic diseases, blood cancers, and severe autoimmune disorders. | Biotech | Basel, Switzerland | Series A | $50.0M | 2022-04-13 | $50.0M | Versant Ventures | 11 to 50 | 2020 |
| Embion Technologies | Embion Technologies offers industrial biomass processing technology for nutrition, pharma, and cosmetics applications. | Biotech | Lausanne, Switzerland | Series A | $4.9M | 2021-12-08 | Venture Kick, Foundation for Innovation and Technology (FIT), Swiss Economic Award | 1 to 10 | 2016 | |
| Platomics | Platomics is an accelerator program for in vitro diagnostics companies. | Biotech | Vienna, Austria | Series A | $16.4M | 2021-09-21 | $16.4M | GreyBird Ventures | 101 to 250 | 2014 |
| Anjarium Biosciences | Anjarium Biosciences develops non-viral gene therapies to treat genetic diseases. | Biotech | Schlieren, Switzerland | Series A | $60.4M | 2021-09-15 | Gimv, Omega Funds, Pfizer Venture Investments +2 | 1 to 10 | 2017 | |
| Cortical.io | Cortical.io offers AI solutions for intelligent document processing based on neuroscience-inspired technology. | Artificial intelligence | Vienna, Austria | Series A | $6.0M | 2021-09-14 | $21.3M | European Investment Bank, Open Field Capital | 11 to 50 | 2011 |
| GeneQuine Biotherapeutics | GeneQuine Biotherapeutics develops gene therapy for treating osteoarthritis. | Biotech | Hamburg, Germany | Series A | $6.6M | 2021-02-15 | HTGF (High-Tech Gruenderfonds), IFB Innovationsstarter, Meusinvest (Noshaq) | 1 to 10 | 2011 | |
| Chord Therapeutics | Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases. | Biotech | Geneva, Switzerland | Series A | $16.0M | 2020-10-13 | Omega Funds, Eclosion SA | 1 to 10 | 2014 | |
| POLYNEURON | Polyneuron is a pharmaceutical company developing a new drug class for autoimmune disorders. | Biotech | Basel, Switzerland | Series A | $15.4M | 2020-09-16 | $45.0M | New Enterprise Associates, Venture Kick, Sofinnova Partners +1 | 1 to 10 | 2014 |
| Arvelle Therapeutics | Arvelle Therapeutics is a biopharmaceutical company developing medicines for patients. | Biotech | Basel, Switzerland | Series A | $42.7M | 2020-05-27 | KB Investment, F-Prime, EQT Life Sciences +2 | 51 to 100 | 2019 |
Table 1. Biotech startups that raised Series A in DACH: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 130.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| 2 | Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne, Switzerland | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| 3 | Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne, Switzerland | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| 4 | mbiomics | mbiomics is a biotechnology company. | Biotech | Munich, Germany | Series A | $12.0M | 2026-04-28 | $26.1M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital | 11 to 50 | 2020 |
| 5 | Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld, Germany | Series A | $11.5M | 2026-03-18 | $24.0M | HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 | 1 to 10 | 2018 |
| 6 | Cellbox Solutions | Cellbox Solutions provides logistics solutions for the global biomedical industry. | Biotech | Cologne, Germany | Series A | $1.7M | 2026-10-20 | $15.3M | European Innovation Council, Fraunhofer Venture, CK Venture Capital | 11 to 50 | 2017 |
Table 2. Biotech startups that raised Series A in DACH: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 22 | 17% | 2 | mbiomics, Kupando |
| 2 | Venture Kick | Startup incubator | Schlieren, Switzerland | 10 | 8% | 1 | Adaptyv Biosystems |
| 3 | KfW | Government investment office | Frankfurt, Germany | 6 | 5% | ||
| 4 | Foundation for Innovation and Technology (FIT) | Entrepreneurship program | Lausanne, Switzerland | 5 | 4% | 1 | Adaptyv Biosystems |
| 5 | Bayern Kapital | Venture capital firm | Landshut, Germany | 5 | 4% | 1 | mbiomics |
| 6 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 5 | 4% | 1 | FoRx Therapeutics |
| 7 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 4 | 3% | 1 | FoRx Therapeutics |
| 8 | Omega Funds | Secondary purchaser | Boston, United States | 4 | 3% | 1 | FoRx Therapeutics |
| 9 | BioMedPartners | Venture capital firm | Basel, Switzerland | 4 | 3% | ||
| 10 | Fraunhofer Venture | Venture capital firm | Munich, Germany | 3 | 2% | 1 | Cellbox Solutions |
| 11 | European Innovation Council | Startup accelerator | Brussels, Belgium | 3 | 2% | 1 | Cellbox Solutions |
| 12 | Andera Partners | Private equity firm | Paris, France | 3 | 2% | ||
| 13 | Versant Ventures | Venture capital firm | Menlo Park, United States | 3 | 2% | ||
| 14 | Gilde Healthcare | Private equity firm | Utrecht, The Netherlands | 3 | 2% | ||
| 15 | EMBL Ventures | Venture capital firm | Heidelberg, Germany | 3 | 2% |
Table 3. Biotech startups that raised Series A in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 102 | 78% | $1.2B |
| Software | 13 | 10% | $123.3M |
| Artificial intelligence | 9 | 7% | $106.9M |
| Hardware | 2 | 2% | |
| Fintech | 1 | 1% | $21.3M |
| Education | 1 | 1% |
Table 4. Biotech startups that raised Series A in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 130 | 100% | $8.9M |
Table 5. Biotech startups that raised Series A in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Germany | 58 | 45% |
| Switzerland | 56 | 43% |
| Austria | 15 | 12% |
| Liechtenstein | 1 | 1% |
Table 6. Biotech startups that raised Series A in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Basel | 13 | 10% |
| Lausanne | 10 | 8% |
| Vienna | 10 | 8% |
| Schlieren | 6 | 5% |
| Munich | 5 | 4% |
| Geneva | 5 | 4% |
| Hamburg | 5 | 4% |
| Berlin | 5 | 4% |
| Martinsried | 4 | 3% |
| Epalinges | 4 | 3% |
| Zürich | 3 | 2% |
| Neuchâtel | 3 | 2% |
Table 7. Biotech startups that raised Series A in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 2 | 17% | $6.5M |
| September 2026 | 2 | 17% | $13.7M |
| August 2026 | 1 | 8% | $40.0M |
| April 2026 | 2 | 17% | $32.5M |
| March 2026 | 2 | 17% | $22.8M |
| January 2026 | 1 | 8% | $28.8M |
| December 2025 | 2 | 17% | $70.0M |
Table 8. Biotech startups that raised Series A in DACH: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 10 | 8% | $144.3M |
| 2025 | 8 | 6% | $230.0M |
| 2024 | 13 | 10% | $258.7M |
| 2023 | 7 | 5% | $153.7M |
| 2022 | 6 | 5% | $193.5M |
| 2021 | 16 | 12% | $298.2M |
Table 9. Biotech startups that raised Series A in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 2% |
| 2020 to 2022 | 17 | 13% |
| 2015 to 2019 | 43 | 33% |
| 2010 to 2014 | 35 | 27% |
| Before 2010 | 31 | 24% |
Table 10. Biotech startups that raised Series A in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 47 | 37% |
| 11 to 50 | 65 | 51% |
| 51 to 100 | 10 | 8% |
| 101 to 250 | 3 | 2% |
| 251 to 500 | 1 | 1% |
| 501 to 1,000 | 2 | 2% |
Table 11. Biotech startups that raised Series A in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in DACH. On 16 November 2026 that is 130 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 130 rows: 27 have no round amount, 0 no city and 59 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in DACH whose last round is Series A are on the list?
- 130, in the file dated 16 November 2026. 12 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 130 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.